Stock Ratings / Health Care / FHTX / insiders

BGM (35) NKTX (31) CLLS (49) HURA (40) ⌘ Pro Terminal →

Foghorn Therapeutics Inc. (FHTX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Where is FHTX trading relative to its 50-day, 200-day, and 52-week technical levels?

FHTX last traded at $2.08 (-0.48% on volume of 555,613 shares), positioning the stock -42.22% below its 50-day simple moving average ($3.60) and -55.84% below its 200-day simple moving average ($4.71). Across its 52-week range of $1.79 to $7.61, FHTX sits at the 5.0% percentile with a 14-day RSI of 30.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.82 to $2.34).

Q: Are FHTX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies FHTX leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$2.08 -0.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.07

Foghorn Therapeutics Inc. (FHTX) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $124.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FHTX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FHTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Foghorn Therapeutics Inc. (NASDAQ: FHTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $2.08 (-0.48% 1D, market cap $124.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FHTX ranks #775 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FHTX compare to BGM and NKTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), FHTX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BGM (BGM Group Ltd. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC —, cap $127.4M) and NKTX (Nkarta Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $118.9M). Among the 5-stock peer group, FHTX leads on earnings multiple (N/A) while FHTX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FHTX?

▼

Per FHTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001822462), Foghorn Therapeutics Inc. generated $30.9M in revenue (+36.8% YoY), -$74.3M in net income, and -$86.1M in free cash flow against $198.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.07 (-0.28%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FHTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY FHTX SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (41% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 30.4 (OVERSOLD (<32))

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.00-7.5% Next Q

Q2 (-2Q)

Grade E$1.85+8.1% Next Q

Q3 (-1Q)

Grade E$2.00+4% Next Q

Current

Grade E$2.08-9.2% Hist 90D α

Trajectory: E (24) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FHTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FHTX currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.60) and Max Pain ($2.18) forces dealer call-delta covering toward $7.99.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FHTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FHTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

FHTX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (FHTX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on FHTX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FHTX)

✓Walkthrough of FHTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FHTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.21%📐 HORIZONTAL RANGE

2026-10-30O $2.08H $2.09L $2.01C $2.08VOL 555.6K

RES: $9.29SUP: $0.51SMA50: $3.60SMA200: $4.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FHTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FHTX Butterfly Map → + Track FHTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +36.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FHTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FHTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FHTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FHTX)

Health Care Rank #775 of 1016 ⚔️ BGM vs FHTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FHTX vs. BGM, NKTX, CLLS, HURA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Foghorn Therapeutics Inc. (FHTX) ranks #775 by composite RQD confidence (32/100, grade E) and #632 by equity capitalization ($124.1M). Within this direct 5-issuer industry benchmark cohort, FHTX leads on earnings valuation at N/A trailing P/E, while FHTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CLLS currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with FHTX at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FHTX ACTIVE Foghorn Therapeutics Inc.	E	32/100	—	—	-35.0%	-0.48%	$124.1M	Benchmark Subject
BGM BGM Group Ltd. (Class A)	D-	35/100	—	16.6%	—	0.00%	$127.4M	/bgm-vs-fhtx →
NKTX Nkarta Inc.	E	31/100	—	—	-35.0%	-6.02%	$118.9M	/nktx-vs-fhtx →
CLLS Cellectis S.A.	D	49/100	—	—	—	-7.69%	$117.6M	/clls-vs-fhtx →
HURA TuHURA Biosciences Inc.	D-	40/100	—	—	-35.0%	-6.31%	$131.3M	/hura-vs-fhtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001822462

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Foghorn Therapeutics Inc. (FHTX) reported GAAP revenue of $30.9M (+36.8% vs. FY2024 revenue of $22.6M , and -9.5% cumulative change since FY2023) , GAAP net income of -$74.3M, operating cash flow of -$86.1M, and free cash flow of -$86.1M (+15.0% YoY). On the balance sheet, FHTX closed FY2025 with $198.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$30.9M	-$74.3M	-$86.1M	-$86.1M	$198.1M	—
FY2024 (FY)	2024-12-31	$22.6M	-$86.6M	-$100.4M	-$101.3M	$284.0M	—
FY2023 (FY)	2023-12-31	$34.2M	-$98.4M	-$118.1M	-$118.1M	—	—

3. FHTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FHTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does FHTX compare to BGM and NKTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for FHTX?

Where is FHTX trading relative to its 50-day, 200-day, and 52-week technical levels?

FHTX last traded at $2.08 (-0.48% on volume of 555,613 shares), positioning the stock -42.22% below its 50-day simple moving average ($3.60) and -55.84% below its 200-day simple moving average ($4.71). Across its 52-week range of $1.79 to $7.61, FHTX sits at the 5.0% percentile with a 14-day RSI of 30.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.82 to $2.34).

FHTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are FHTX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies FHTX leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: FHTX RQD Cockpit FHTX 12M Forecast FHTX Earnings & Move FHTX Dividends & DRIP FHTX Insiders & 13F FHTX Whale Options FHTX Profit Sankey FHTX News & Why

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

FHTX — Foghorn Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:16Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, FHTX scores 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 2/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow at 9/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 13/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 5/20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are the cash engine and forensic balance sheet, which indicate that the company's reported economics do not currently generate cash returns and that its solvency screens are weak. The strongest pillar, macro regime fit at 13/20, reflects only a beta of 1.0 and sector sensitivity, not an earnings-based upside case. Any valuation tradeoff therefore rests on whether the cash-burn profile improves, which the rating does not establish. The lowest-scoring signal, insider conviction at 3/20, adds no positive offset to the fundamental weakness.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$30.9M	$-86.4M	$-74.3M	N/A	$-86.1M	$80.9M	N/A
FY 2024	$22.6M	$-102.7M	$-86.6M	N/A	$-101.3M	$55.5M	N/A
FY 2023	$34.2M	$-107.9M	$-98.4M	N/A	$-118.1M	N/A	N/A

Per the SEC financials, the company reported operating and net losses across all three periods, with operating margin of -60% and net margin of -60% per market data, and gross margin of 0%. ROIC is -35% per market data. The Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, both per the Roarable RQD rating. Debt/Equity is 0.5 per the same rating, while reported debt values are N/A in the financial table. Cash rose to $80.9M in FY 2025 from $55.5M in FY 2024 per the SEC financials.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the items are:

Earnings expectation (GREEN, CATALYST): Yahoo Finance headline states the company is expected to beat earnings estimates.
Fair value revision (YELLOW, MARKET WIRE): Yahoo Finance reports fair value moving lower after a pipeline and Lilly reset.
Analyst downgrade (RED, RISK WATCH): Seeking Alpha reports a "Sell" downgrade tied to Eli Lilly exiting FHD-909 and a shift to preclinical assets.
Legal investigations (RED, RISK WATCH): Business Wire and PR Newswire items report law-firm investigations of claims on behalf of investors.
Sector roundup (RED, RISK WATCH): kalkine.ca places the company among biotech names covered for data, downgrades, and disruption.

Per the Butterfly Supply-Chain Graph, the supply chain is "NONE," with no butterfly links and no proprietary signals.

Open Questions

What are the company's products, indications, and revenue sources, given that the source data gives no business description beyond sector classification?
What is the status of the Eli Lilly relationship and the FHD-909 program, and how does the exit affect the revenue reported in FY 2025 and FY 2024?
What explains the gap between reported cash ($80.9M in FY 2025) and the FY 2025 FCF of $-86.1M, and what is the runway at that burn rate?
What are the nature and scope of the investor investigations referenced in the news feed?
What are the debt obligations, since the debt field is N/A in every period despite a reported Debt/Equity of 0.5?

FHTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Foghorn Therapeutics Inc. (FHTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FHTX Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 6h ago

Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy?

Yahoo Finance report covering Foghorn Therapeutics Inc. (FHTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 9h ago

Foghorn Therapeutics (FHTX) Stock Fair Value Moves Lower After Pipeline And Lilly Reset

Yahoo Finance report covering Foghorn Therapeutics Inc. (FHTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Seeking Alpha • 12h ago

Foghorn: Downgrade "Sell" Eli Lilly Exit FHD-909 And Shift To Preclinical Assets

Seeking Alpha report covering Foghorn Therapeutics Inc. (FHTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Business Wire • 15h ago

FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law

Business Wire report covering Foghorn Therapeutics Inc. (FHTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE PR Newswire • 18h ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

PR Newswire report covering Foghorn Therapeutics Inc. (FHTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH kalkine.ca • 21h ago

Data, Downgrades and Disruption: Monte Rosa (NASDAQ:GLUE), Foghorn (NASDAQ:FHTX), Integra LifeSciences (NASDAQ:IART) and Six Other Biotech Stocks

kalkine.ca report covering Foghorn Therapeutics Inc. (FHTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

Evercore ISI Downgrades Foghorn Therapeutics to In Line, $3 Price Target

Yahoo Finance report covering Foghorn Therapeutics Inc. (FHTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Foghorn Therapeutics Inc. (FHTX) Seasonal returns chart

Yahoo Finance UK report covering Foghorn Therapeutics Inc. (FHTX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FHTX Bull vs. Bear Conversation Board — What's Your Call at $2.08?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FHTX 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.83 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is FHTX (E • RQD 32/100) a Buy at $2.08?

Welcome to the FHTX (Foghorn Therapeutics Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.58 (-24.0%)

Spot @ $2.08

Pump the brakes on FHTX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on FHTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Foghorn Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.43 (+16.8%)

Spot @ $2.08

FHTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on FHTX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.08 (52-wk range $1.79 - $7.61), any beat on forward guidance forces shorts and underweight funds to chase.